Virginia Beach, VA. – September 30, 2014- Global Holdings, Inc. (GBHD.OTC) announces that it has signed a “Letter of Intent” to acquire exclusive licensed rights for a pharmaceutical product for the treatment of endometriosis. This product has a patent -pending application with the US Patent and Trademark Office.
Endometriosis, one of the most common gynecological disorders that is estimated to affect approximately one in ten women in their reproductive (child-bearing) years and is the number one cause of infertility.
Management believes this pharmaceutical product that is being developed and commercialized using FDA approved novel compounds will stop the progression of the diseases with minimal adverse side effects. There are an estimated 27.5 million symptomatic women in the US and additional over 100 million worldwide who suffer from endometriosis. In the US, only an estimated 2.5 million have been diagnosed and are being treated for endometriosis.
This pharmaceutical application was developed to halt development and progression of the often painful, debilitating, and aging symptoms of endometriosis in women. The only way to diagnose endometriosis today is an invasive laparoscopy that requires general anesthesia with a cost of $8,000 to $20,000. Over 50% of the time endometriosis is NOT found as a result of the limits associated with diagnostic laparoscopy.
This novel pharmaceutical compound completely suppresses endometriosis in women before and after the on-set of the disease.
For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, #757-306-6090, www.gbhd.net.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competitions.